🔫 ATF Updates Gun Purchase Form to Reflect Medical Marijuana’s New Federal Status

The Bureau of Alcohol, Tobacco, Firearms and Explosives has proposed revisions to its federal gun purchase form (Form 4473) that for the first time distinguish between medical and recreational marijuana use, reflecting cannabis’s recent move to Schedule III under federal law. The updated lan guage removes the blanket warning that all marijuana use is illegal and instead specifies that only recreational use remains prohibited, signaling that state‑legal medical cannabis patients may no longer automatically be considered “unlawful users” for firearm eligibility purposes. While the change could reduce barriers for medical marijuana patients seeking to purchase firearms, it is still a proposed update subject to public comment and does not fully resolve ongoing legal uncertainty around cannabis use and gun rights under federal law. (Marijuana Moment)

⚠️ Former Federal Prosecutor and IRS Lawyer Warn Cannabis Industry on DEA Registration Risks

Legal experts including a former federal prosecutor and a former IRS attorney are cautioning cannabis businesses against rushing into the DEA’s new Schedule III registration process, warning that the federal rescheduling of medical marijuana creates a complex and uncertain legal landscape rather than immediate protection. They emphasize that while registration could offer benefits like tax relief and federal recognition, it may also expose companies to scrutiny over past activities that were federally illegal, especially given longstanding rules that prioritize prior compliance with federal law when evaluating applicants. The takeaway, they say, is that businesses should carefully assess legal and tax risks with professional guidance before applying, as the evolving framework still leaves significant ambiguity around enforcement, compliance and potential liability. (Cannabis Business Times)

⚕️ Federal Hemp Ban Could Undermine Medicare and Medicaid CBD Coverage Efforts

Scientists discovered that removing a key enzyme (DAGLα) in the cerebellum disrupted the brain’s endocannabinoid system in mice, making them more anxious and less social. The enzyme normally produces 2-AG, a chemical messenger that helps neurons fine-tune their communication. Without it, the mice’s brain cells were less adaptable, affecting both movement and emotions. Researchers say the findings could lead to targeted therapies to boost endocannabinoid signaling and improve quality of life for people with autism, anxiety, and other social or emotional challenges.

👉 Read The Full Study Here

🆓 Medicare Pilot Program Tests CBD for Seniors as Federal Policy Evolves

A New York Times report highlights a new federal pilot program allowing some Medicare patients to receive hemp‑derived CBD products at no cost as part of an effort to evaluate whether they can relieve symptoms like pain, anxiety and insomnia while potentially lowering overall health care costs. The initiative reflects growing use of CBD among older Americans and aims to generate real‑world medical data, though doctors caution about risks such as drug interactions and the lack of FDA‑approved standards, emphasizing the need for physician oversight. The program is limited and experimental, but its results could influence whether CBD becomes more widely integrated into mainstream healthcare for seniors. (NY Times)

🗓️ Continued Cannabis News & Events

• No evidence it helps: Doctors warn against adolescents self-medicating with cannabis

• Cannabis and tobacco co-use increases psychosis chances in high-risk cohorts: Study

• ‘There Are A Lot Of People Who Smoke Cannabis In Congress,’ Lawmaker Says

• Indiana State Senator to write legislation in 2027 that would legalize medical marijuana